Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015–16

Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate

(2017) Anna Both et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

FRI-2 carbapenemase-producing Enterobacter cloacae complex in the UK

(2017) Danièle Meunier et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria

(2017) David M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

OXA-48-like carbapenemases in the UK: an analysis of isolates and cases from 2007 to 2014

(2017) Jacqueline Findlay et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace

(2017) Latania K. Logan et al.   JOURNAL OF INFECTIOUS DISEASES

Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study

(2017) Hajo Grundmann et al.   LANCET INFECTIOUS DISEASES

Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.

(2016) Ryan K. Shields et al.   CLINICAL INFECTIOUS DISEASES

Multicentre evaluation of a real-time PCR assay to detect genes encoding clinically relevant carbapenemases in cultured bacteria

(2016) Matthew J. Ellington et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Detection of the plasmid-mediatedmcr-1gene conferring colistin resistance in human and food isolates ofSalmonella entericaandEscherichia coliin England and Wales

(2016) Michel Doumith et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In VitroSelection of Ceftazidime-Avibactam Resistance in Enterobacteriaceae with KPC-3 Carbapenemase

(2015) David M. Livermore et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Structural Basis for Different Substrate Profiles of Two Closely Related Class D β-Lactamases and Their Inhibition by Halogens

(2015) Vlatko Stojanoski et al.   BIOCHEMISTRY

Activity of ceftazidime/avibactam against isogenic strains ofEscherichia colicontaining KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop

(2015) Marisa L. Winkler et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The β-Lactams Strike Back: Ceftazidime-Avibactam

(2015) Evan J. Zasowski et al.   PHARMACOTHERAPY

New β-lactam-β-lactamase inhibitor combinations in clinical development

(2013) David M. Shlaes   Annals of the New York Academy of Sciences

Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases

(2013) David E. Ehmann et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Rapid acquisition of decreased carbapenem susceptibility in a strain of Klebsiella pneumoniae arising during meropenem therapy

(2011) J. Findlay et al.   CLINICAL MICROBIOLOGY AND INFECTION

Expert Systems in Clinical Microbiology

(2011) T. Winstanley et al.   CLINICAL MICROBIOLOGY REVIEWS

Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-ProducingEnterobacteriaceae

(2010) David M. Livermore et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters

(2010) S. Mushtaq et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

PCR characterization and typing of Klebsiella pneumoniae using capsular type-specific, variable number tandem repeat and virulence gene targets

(2010) J. F. Turton et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK

(2009) M. Doumith et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Development of ertapenem resistance in a patient with mediastinitis caused by Klebsiella pneumoniae producing an extended-spectrum  -lactamase

(2009) D. Skurnik et al.   JOURNAL OF MEDICAL MICROBIOLOGY